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ABSTRACT
Regulation of microRNA (miR) biogenesis is com-
plex and stringently controlled. Here, we identify the
kinase GSK3 as an important modulator of miR
biogenesis at Microprocessor level. Repression of
GSK3 activity reduces Drosha activity toward pri-
miRs, leading to accumulation of unprocessed pri-
miRs and reduction of pre-miRs and mature miRs
without altering levels or cellular localisation of miR
biogenesis proteins. Conversely, GSK3 activation
increases Drosha activity and mature miR accu-
mulation. GSK3 achieves this through promoting
Drosha:cofactor and Drosha:pri-miR interactions: it
binds to DGCR8 and p72 in the Microprocessor, an
effect dependent upon presence of RNA. Indeed,
GSK3 itself can immunoprecipitate pri-miRs, sug-
gesting possible RNA-binding capacity. Kinase as-
says identify the mechanism for GSK3-enhanced
Drosha activity, which requires GSK3 nuclear local-
isation, as phosphorylation of Drosha at S300 and/or
S302; confirmed by enhanced Drosha activity and as-
sociation with cofactors, and increased abundance
of mature miRs in the presence of phospho-mimic
Drosha. Functional implications of GSK3-enhanced
miR biogenesis are illustrated by increased levels
of GSK3-upregulated miR targets following GSK3
inhibition. These data, the first to link GSK3 with
the miR cascade in humans, highlight a novel pro-
biogenesis role for GSK3 in increasing miR biogen-
esis as a component of the Microprocessor complex
with wide-ranging functional consequences.
INTRODUCTION
MicroRNAs, first identified in 1993, are 18–22 nucleotide
non-coding RNAs. The accepted dogma is that they neg-
atively regulate gene expression through association with
complementary sequences within target gene 3′UTRs, lead-
ing to transcript degradation and/or translational inhi-
bition (1,2). A single transcript can be targeted by hun-
dreds of miRs, and individual miRs can target hundreds of
genes, hence the regulatory activity ofmiRs is being increas-
ingly accepted as a complex network of tissue-and disease-
specific interactions (3,4). MiRs are transcribed by RNA
polymerase II, generating a primary microRNA transcript
(pri-miR), which is then 5′ capped and adenylated (5). The
majority of pri-miRs are polycistronic and generate several
functional mature miRs. The pri-miR is cleaved into one or
more∼70 nt hairpin-structured precursormiRs (pre-miRs),
by the Drosha-containing Microprocessor (MP) complex
(6). Drosha, an RNase III enzyme, is stabilised by associ-
ation with double-stranded RNA binding domain protein
DiGeorge Critical Region 8 (DGCR8)/Partner of Drosha
(Pasha) (7). Other cofactors such as p72, p68, FUS and hn-
RNPA1modulate fidelity, efficiency and specificity of cleav-
age or act as scaffold proteins to aid complex formation (8).
Some cofactors alter biogenesis of the entire miRNAome,
others demonstrate activity against a defined miR subset.
Thus, theMP is very large multi-protein complex (>650 kD
in human cells (9)) containing at least 20 different polypep-
tides. Drosha cleavage generates a 2 nt 3′ overhang, vital
both for recognition by Exportin-5, which facilitates Ran-
GTP-dependent export of the pre-miR to the cytoplasm,
and for cleavage of the stem-loop by a second RNase III
enzyme, Dicer (10,11). Optimal Dicer activity requires the
accessory dsRBD protein TRBP/PACT, and yields a ∼22
nt miR duplex. The two strands separate and one strand
associates with Argonaute-2 (AGO2), a protein component
of the RNA-induced silencing complex (RISC). Themature
miR guides RISC to complementary sequences within the
3′UTR of target mRNAs, resulting in translational repres-
sion and/or transcript degradation.
MiR biogenesis is emerging as a stringently controlled
and remarkably complex pathway, about which much re-
mains to be learnt. Coordinated regulation, including
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feedback from miR targets, likely serves to prevent mis-
expression of miRs both spatially and temporally, safe-
guarding sophisticated transcriptional processes. MiR pro-
cessing is thought to be particularly important in develop-
ment and tumourigenesis. For example, in early develop-
ment many pri-miRs are expressed but not efficiently con-
verted into their mature forms (12). Equally, reduced pro-
cessing has been shown to contribute to widespread down-
regulation of many miRs in human cancers (11,13,14).
Glycogen synthase kinase 3 (GSK3) is a
serine/threonine protein kinase, initially identified as
a regulator of glycogen metabolism, that has been shown
to perform vital roles in a number of essential cellular
signalling pathways, including Wnt/-catenin, Hedgehog,
Notch and Insulin signalling (15). It plays a key role
in signal transduction during processes such as cell cycle
progression, proliferation and inflammation. GSK3 phos-
phorylates diverse target proteins, and is itself regulated
by phosphorylation. Its activity is decreased by Ser9 phos-
phorylation, mediated by the serine/threonine kinase Akt
(a component of the PI3K/MAPK signalling pathway),
MAPK-activated protein kinase-1 or p70 ribosomal S6
kinase-1. In contrast, phosphorylation at Tyr216 results in
activation of GSK3 and is believed to be vital for signal
transduction in resting cells (16). It has been established
that more than 40 proteins are substrates for GSK3 (17),
including cyclin D1 (18) and the transcription factors AP1,
NFB, c-Jun, GR and Notch (19–21), permitting highly
sensitive regulation of cell cycle progression in response to
extracellular stimuli.
GSK3 initially gained prominence as a drug target in
treatment of diabetes mellitus and obesity (22,23). It also
plays important roles in signal transduction in several key
neurotransmitter pathways so is linked to mood disorders,
bipolar disorder, depression and schizophrenia, and the
GSK3 inhibitors lithium and valproate are currently used
to treat such conditions (24,25). In cancer, GSK3 has been
implicated in development and progression of breast (26),
brain (27), pancreatic (28), colon (29) and prostate tumours
(30), although it displays disparate activity in differing tis-
sues and tumour types. In breast cancer cells, activation
of GSK3 by rapamycin induces downregulation of cyclin
D1, cell cycle arrest and inhibition of anchorage-dependent
growth (26). GSK3 may also play a role in preventing ep-
ithelial to mesenchymal transition (EMT) in tumourigen-
esis, as its inhibition promotes EMT in cultured epithelial
cells (31). In contrast, GSK3 overexpression has been ob-
served in ovarian, colon and pancreatic tumours (21) result-
ing in enhanced proliferation and survival of ovarian cancer
cells in vivo and in vitro (32). Additionally, GSK3 inhibi-
tion suppressed ovarian cancer cell proliferation in vitro (32)
and decreased growth and survival of colon cancer cells in
vivo (29).
It was recently shown that inhibition of GSK3 using
small molecule inhibitors decreases levels of the majority of
mature miRs in mouse embryonic stem cells, the data sug-
gesting a reduction in nuclear Drosha levels in such cells
may be responsible (33). It has also been reported that
GSK3 phosphorylates Drosha at residues S300 and S302
(34). Impacts of such modifications, and of GSK3 inhi-
bition, on Drosha’s essential ribonuclease activity and miR
biogenesis were, until now, unknown. The data presented
here are the first to describe a mechanism for GSK3 regu-
lation of miR biogenesis as a regulatory component of the
MP. We demonstrate that GSK3 enhances Drosha asso-
ciation with its cofactors, DGCR8 and p72 and increases
Drosha:pri-miR binding to enhance pri-miR cleavage. This
is achieved through direct binding of GSK3 to DGCR8
and p72 within the Microprocessor in an RNA-dependent
manner. In addition, we have shown that GSK3-mediated
phosphorylation of Drosha at S300 and S302 increases miR
biogenesis not through altered Drosha localisation, but
by enhancing Drosha:DGCR8 interaction. We hypothesise
that GSK3 constitutes a ‘missing link’ between essential
mitogenic signalling pathways and miR biogenesis.
MATERIALS AND METHODS
Mammalian cell culture
Cells weremaintained at 37˚C in 5%CO2.HeLa,HEK293T
and COS-1 cells were maintained in Dulbecco’s Modified
Eagle’s Medium (Sigma), LNCaP and PC3 cells were main-
tained and passaged in RPMI-1640 (Sigma). All media sup-
plemented with 10% fetal bovine serum, 100 U/ml peni-
cillin, 100 g/ml streptomycin and 2 mM L-glutamine
(Sigma).
Cell lysis, Western blotting and antibodies
Cells were lysed and protein extracted as described (35).
Proteins were resolved by 8–12% SDS-polyacrylamide gel
electrophoresis and electroblotted to nitrocellulose mem-
brane (Bio-Rad). After blocking (5% non-fat dried milk
powder in 0.05% Tween-20 in 1xPBS, or 5% BSA in TBST
for phospho-proteins) for 40 min, membranes were incu-
bated with rabbit anti-Drosha pAb (Sigma, SAB4200151),
mouse anti-GSK3 mAb (Abcam, ab93926), rat anti-
AGO2 Ab (gift from Geok Tan, Imperial College Lon-
don), mouse anti-FUS mAb (SantaCruz, sc-47711), mouse
anti-Flag epitope tag M2 mAb (Sigma, F1804), rabbit anti-
DGCR8 pAb (Sigma, SAB4200089), rabbit anti-DGCR8
pAb (Abcam ab36865), mouse anti-HA mAb (Covance,
16B12), mouse anti-phospho-serine (Sigma P5747), rab-
bit anti-PTEN pAb (R+D systems, AF847), rabbit anti-
FOXO1 mAb (Abcam, ab52857), rabbit anti-ZEB1 mAb
(Cell Signalling, 3396), mouse anti--tubulin mAb (Sigma,
T4126) or mouse anti--actin mAb (Abcam, ab6276) for
1 h and visualised using goat anti-mouse, goat anti-rabbit
or goat anti-rat IgG-HRP as appropriate. Detection was by
Luminata Forte HRP substrate (Millipore).
Plasmid stocks
pCK-Flag-Drosha construct was a kind gift from Prof.
V. Narry Kim, Seoul University. pCK-Flag-Drosha-
S300A,S302A and pCK-Flag-Drosha-S300E,S302D plasmids
were generated by site-directed mutagenesis of the pCK-
Flag-Drosha vector using the QuikChange Lightning
Site-Directed Mutagenesis Kit (Stratagene). pMT23-
c-Myc-GSK3-S9A and pMT23-HA-GSK3-K85R
plasmids were generously gifted by Dr Robert Kypta,
Imperial College London. pMT23-HA-GSK3 (wild-type)
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and pMT23-HA-GSK3-S9A plasmids were generated
by site-directed mutagenesis of the pMT23-HA-GSK3-
K85R vector as above. CMV-pri-miR-23a27a24-2-GL4.18
Drosha activity reporter vector was constructed as previ-
ously described (36). pGEMT Easy-pri-miR-23a27a24-2
was generated by insertion of the genomic miR-23a27a24-2
sequence into the multiple cloning site. pMiRTarget-ACLY
3′UTR was a kind gift of Dr Hector Keun (Imperial
College London), generated by insertion of the full-length
ACLY 3′UTR 3′ of the luciferase gene in the pMiRTarget
vector. pMiRTarget-ACLY 3′UTR miR-27a binding site
(BS) mutant was generated by G→U point mutation of
the pMiRTarget-ACLY 3′UTR vector at nucleotide 700 of
the ACLY 3′UTR. This nucleotide is located in the centre
of the miR-27a seed region binding site (Supplementary
Figure S9).
Drosha cleavage activity reporter luciferase assays
The CMV-pri-miR-23a27a24-2-GL4.18 Drosha activity re-
porter vector was cotransfected into Cos-1 or HEK293T
cells alongside pMT23-HA-GSK3-S9A or pMT23-HA-
GSK3-K85R mutant GSK3 expression vectors, or pCK-
Flag-Drosha or pCK-Flag-Drosha-S300E,S302DDrosha ex-
pression vectors as appropriate using the calcium phos-
phate method (37). Twenty-four hours post-transfection,
cells were treated with the GSK3 inhibitor, 99021, if re-
quired and harvested after a further 24 h. Luciferase assays
were performed using the Luclite assay (Packard, USA)
and activity normalised for transfection efficiency using the
Galacton kit (Tropix) as previously described (38).
MiR, pre-miR, pri-miR and mRNA quantitative real-time
PCR
Mature miR expression was quantified by quantitative real-
time RT-PCR using TaqMan microRNA assays and Taq-
Man Universal PCRMaster Mix (Applied Biosystems) ac-
cording to the manufacturer’s protocol. For detection of
pri-miRs, Drosha coding region and ACLY, ZEB1, PTEN
or FOXO1 3′UTRs, cDNA was prepared from 500 ng to-
tal RNA using Precision qScript Reverse Transcription kit
(PrimerDesign) and oligo d(T) primers. cDNAswere ampli-
fied using either (i) 2x Fast SYBR Green Master Mix (Ap-
plied Biosystems) and 250 nM forward and reverse primers
(see Supplementary Table S1), or (ii) TaqMan pri-miR
assays (Applied Biosystems) for pri-miR-23a27a24-2, pri-
miR-141/200c and pri-miR-182 and 2x Taqman Fast Uni-
versal PCR Master Mix No AmpErase UNG as per man-
ufacturer’s instructions. For detection of pre-miRs, small
RNAs (<200 nt) were isolated using the miRVana MiRNA
Isolation Kit (Ambion). A total of 500 ng RNAwas reverse
transcribed using Precision qScript Reverse Transcription
kit (PrimerDesign) and random nonamers. cDNAs were
amplified using 2x Fast SYBR Green Master Mix (Applied
Biosystems) and 250 nM forward and reverse primers to
pre-miR-27a (see Supplementary Table S1). All data were
analysed using the Ct method, with U18 and L19 as
endogenous references for miR and mRNA/pre-miR/pri-
miR levels respectively, using DMSO/ethanol-treated sam-
ples as calibrators where appropriate.
RNA-immunoprecipitation
Full protocol is described in Supplementary Methods.
Briefly, lysates were generated fromHEK293T cells express-
ing exogenous GSK3 mutants and Flag-Drosha and in-
cubated with anti-Flag affinity gel (Sigma) overnight at
4◦C with rotation. Beads were washed, reconstituted with
DNase solution (Qiagen) and treated with proteinase K.
RNA was then extracted from beads using Trizol LS (Life
Technologies) according tomanufacturer’s instructions and
qRT-PCR performed for pri-miRs.
Immunofluorescent cell staining
Cos-1, PC3 or LNCaP cells on coverslips were fixed with
1% formaldehyde in PBS at room temperature for 10 min,
washed in PBS and blocked with 10% goat serum in PBS for
1 h. Primary antibodies (Rb anti-Drosha, Rb anti-DGCR8,
Ms anti-HA and Ms anti-GSK3) were diluted 1/100-
1/200 in 10% goat serum and added to cells for 1 h at room
temperature, as appropriate. Following washing with PBS,
secondary antibodies (Alexa Fluor 488 Goat anti-Mouse
and 594 Goat anti-Rabbit SFX kits, Invitrogen) were di-
luted 1/200 in 10% goat serum and added to cells for 1 h
at room temperature in the dark. Cells were washed briefly
in PBS and coverslips were mounted onto glass slides using
DAPI-containing Vectashield mounting solution. Staining
was visualised using a Zeiss LSM510 confocal microscope.
Flag-Drosha subcellular fractionation
Subcellular fractionation was performed as described (39)
to isolate cytoplasmic, soluble nuclear and chromatin-
bound protein fractions. See Supplementary Methods.
Immunoprecipitation
Immunoprecipitation was performed as described in the
Supplementary Methods. Briefly, lysates were generated
from HEK293T cells expressing exogenous pMT23-
GSK3-WT/ S9A/ K85R/ K85A,K86A and/or Flag-
Drosha-WT/S300A,S302A/S300E,S302D as appropriate,
pre-cleared and incubated with anti-Flag M2 or EZView
anti-HA agarose beads (Sigma) as appropriate at 4◦C
overnight with rotation. Beads were washed in TBS,
followed by RNase A treatment (200 g/ml) for 15 min at
4◦C, as appropriate. Beads were boiled in IP sample load-
ing buffer, pelleted and supernatant subjected to Western
blotting. For immunoprecipitation of endogenous proteins,
lysates were generated from 99021-treated HEK293T
cells and incubated with rabbit anti-Drosha (Cell Sig-
nalling, 3364) or mouse anti-GSK3 (Abcam, ab93926)
antibody-bound Protein G Dynabeads (ThermoFisher)
or anti-phosphoserine–agarose (Sigma-Aldrich, A8076)
as appropriate at 4◦C overnight with rotation. Beads were
washed x3 with Wash Buffer (Dynabeads® Protein G
Immunoprecipitation Kit, ThermoFisher), eluted as above
and subjected to Western blotting.
In vitro pri-miR processing assay
In vitro processing assays were performed as described (40)
with modifications. Briefly, pGemT Easy vector contain-
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ing 652 bp pri-miR-23a27a24-2 sequence was linearised at
a SalI restriction site ∼30 bp 3′ of the end of the pri-
miR sequence. The pri-miR was in vitro transcribed from
the T7 promoter using MEGAscript T7 in vitro transcrip-
tion kit (Ambion) and 0.75 l of -32P-UTP (40 Ci/l,
800 mCi/mmole, Perkin Elmer NEG007C001MC), fol-
lowed by phenol/chloroform extraction. Precipitated RNA
was resolved on a 6% acrylamide:urea gel, which was
exposed to film. -32P-UTP-labelled pri-miR-23a27a24-
2 was cut from the gel and eluted in 0.3 M sodium ac-
etate (pH 5.5), 2% SDS. In vitro processing was performed
by incubation (37◦C, 90 min) of -32P-UTP-labelled pri-
miR-23a27a24-2 with Flag-Drosha immunoprecipitated
from HEK293T cells transfected with pCK-Flag-Drosha
± pMT23-HA-GSK3-WT/S9A/K85R for 48 h. RNA
was phenol/chloroform-extracted and separated on 6% and
12.5% acrylamide:urea gels alongsideDecades RNAMark-
ers (ThermoFisher), which were prepared according to
the manufacturer’s protocol. The gel was exposed to film
overnight at −80◦C in a cassette with intensifying screen.
In vitro kinase assay
Twenty five amino acid peptides were synthesised cor-
responding to WT Drosha 289–313 (RERHRHRD-
NRRSPSLERSYKKEYKR) or S300A,S302A Drosha
289–313 (RERHRHRDNRRAPALERSYKKEYKR),
containing predicted GSK3 phosphorylation sites.
Twenty five micrograms of the above Drosha peptides were
incubated with 150 ng GSK3, 10 M cold ATP and 5 l
( -32P)-ATP (10 Ci/mmol, 2 mCi/ml, Perkin Elmer) in 50
l kinase assay buffer (60 mM HEPES-NaOH pH7.5, 3
mM MgCl2, 3 mM MnCl2, 3 M sodium orthovanadate,
1.2 mM DTT, 0.05 g/l PEG20.000) for 1 h at 30◦C.
Reactions were terminated by incubation at 65◦C for 20
min. A total of 10 l of each reaction was dotted onto
nitrocellulose membrane, left to dry for 2–3 min, washed
x3 with TBST and exposed to X-ray film.
ACLY 3′UTR luciferase reporter assay
pMiRTarget-ACLY 3′UTR WT or pMiRTarget-ACLY
3′UTR miR-27a binding site (BS) mutant were trans-
fected into HEK293T cells alongside the pdmLacZ -
galactosidase reporter plasmid using the calcium phosphate
method (37). Twenty-fours hours post-transfection, cells
were treated with 99021 (2 M) and harvested after a
further 24 h. Luciferase assays were performed using the
Luclite assay (Packard, USA) and activity normalised for
transfection efficiency using the Galacton kit (Tropix) as
previously described (38).
Statistical analysis
Normally distributed continuous variables were assessed
by Student‘s t-test. Strength of correlation between two
normally distributed continuous variables was assessed by
Pearson’s correlation coefficient (r). P ≤ 0.05 was inter-
preted to denote statistical significance.
RESULTS
Inhibition of GSK3 reduces MiR biogenesis through inhibi-
tion of Drosha activity and repression of pri-MiR processing
As GSK3 interacts with and modulates the localisation
of Drosha (34,41), we hypothesised that GSK3 expres-
sion and/or activity may alter pri-miR processing, and
ultimately mature miR levels. To address this, a number
of cell lines were treated with the highly potent and
specific GSK3 inhibitor, 6-(2-(4-(2,4-Dichloro-phenyl)-
5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)-
ethylamino)-nicotinonitrile (known as CT 99021 - CHIR
99021 and referred to as 99021 throughout) (22), or
transfected with a dominant-negative form of GSK3,
GSK3-K85R (42,43) to control for possible off-target
effects of 99021. GSK3-K85R transfection reduced
levels of mature miR-27a, −23a, −141 and −182 by up
to 70% in HEK293T cells (Figure 1A). The same effect
was observed in LNCaP prostate cancer cells following
GSK3-K85R transfection (Supplementary Figure S1A),
and was corroborated by a 50% reduction in levels of
the same mature miRs following 99021 treatment of
LNCaP cells (Supplementary Figure S1B). Further, levels
of corresponding pri-miRs were increased by up to 4-fold
following GSK3-K85R transfection or 99021 treatment of
HEK293T cells (Figure 1B and C); significantly increased
pri-miR levels were also observed following GSK3-K85R
transfection of HeLa cells (Supplementary Figure S1C).
As it has been previously demonstrated that GSK3 can
phosphorylate Drosha and alter its subcellular localisation
(34,41), it was possible that the effects of GSK3 inhibition
on miR maturation may simply be attributable to altered
Drosha localisation. However, 99021 treatment of LNCaP
cells followed by cell fractionation showed no alteration
in nuclear Drosha protein levels (Figure 1D), refuting this
hypothesis. Additionally, decreased miR levels are not at-
tributable to altered protein levels of MP or RISC compo-
nents, since transfection of GSK3-K85R did not alter pro-
tein levels of Drosha, DGCR8, FUS, p72 or of the RISC
component, AGO2 in HEK293T (Figure 1E) or HeLa cells
(Supplementary Figure S1D). In addition, 99021 treatment
of LNCaP prostate cancer cells did not alter Drosha pro-
tein levels (Supplementary Figure S1E). These data indicate
that GSK3 can modulate miR biogenesis without altering
abundance or localisation of key miR biogenesis pathway
proteins.
Since GSK3 inhibition appears to inhibit pri-miR to
mature miR processing, it was hypothesised that 99021-
treatment may alter Drosha activity. To investigate this fur-
ther, a reporter vector was generated in which the genomic
miR-23a27a24-2 sequence is located 5′ of the luc2p gene, un-
der the control of a CMV promoter (Figure 1F). Transcrip-
tion yields the pri-miR-23a27a24-2 linked to the luc2p tran-
script and Drosha-mediated cleavage of the pri-miR dis-
rupts the transcript, resulting in loss of luciferase activity, so
Drosha activity is inversely correlated with luciferase activ-
ity. This approach has been shown to be a sensitive assay for
Drosha-mediated cleavage of a specific pri-miR species in
previous studies (44). Cos-1 cells were transfected with the
Drosha reporter, followed by treatmentwith 99021.A statis-
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Figure 1. Inhibition of GSK3 reduces MiR biogenesis through repression of pri-MiR processing. (A) qRT-PCR analysis of miR-27a, miR-23a, miR-24,
miR-141 and miR-182 levels in HEK293T cells transfected with pMT23-HA-GSK3(K85R) for 48 h. U18 was used as a normalisation gene. (B and
C) qRT-PCR analysis of pri-miR-23a27a24-2 (i), pri-miR-141/200c (ii) and pri-miR-182 (iii) expression from HEK293T cells either (B) transfected with
pMT23-HA-GSK3(K85R), or (C) treated with 99021 (2 M) for 48 h. -Actin was used as normalisation gene. (A, B and C) Columns: mean ± SEM for
three independent experiments performed in triplicate. (D)Western blot analysis of Drosha andMnSODprotein levels in cytoplasmic and nuclear fractions
of LNCaP cells treated with 99021 for 48 h. MnSOD was used as a cytoplasmic control. A representative blot of three independent experiments is shown.
(E) Western blot analysis of Drosha, AGO2, FUS, p72 and DGCR8 protein levels in HEK293T cells transfected with pMT23-HA-GSK3(K85R) for 48
h. -Tubulin was used as a loading control and for normalisation. A representative blot of three independent experiments is shown. (F) Luciferase activity
in extracts of COS-1 cells transfected with 250 ng (i) CMV-GL4 or (ii,iii) CMV-Pri-miR-23a27a24-2-GL4, and treated with (i,ii) 99021 (0,1,2 M), or co-
transfected with 0, 100 or 400 ng (iii) pMT23-HA-GSK3(K85R) for 48 h. Luciferase was normalised for transfection efficiency (-galactosidase activity)
and mean ± SEM of three independent experiments performed in duplicate is shown. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0001. See also Supplementary
Figure S1.
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Figure 2. GSK3 activation enhances MiR biogenesis and GSK3 modulation alters pre-miR synthesis (A) qRT-PCR analysis of miR-27a, miR-23a,
miR-24, miR-141 and miR-182 levels in HEK293T cells transfected with pMT23-HA-GSK3(S9A) for 48 h. U18 was used as a normalisation gene.
(B) qRT-PCR analysis of (i) pri-miR-23a27a24-2, (ii) pri-miR-141/200c and (iii) pri-miR-182 expression from HEK293T cells transfected with pMT23-
HA-GSK3(S9A) for 48 h. -Actin was used as normalisation gene. (A and B) Columns: mean ± SEM for three independent experiments performed in
triplicate. (C) Western blot analysis of Drosha, AGO2, FUS, DGCR8 and p72 protein levels in HEK293T cells transfected with pMT23-HA-GSK3(S9A)
for 48 h. -Tubulin was used as a loading control. (D) Luciferase activity in extracts of COS-1 cells transfected with 250 ng CMV-Pri-miR-23a27a24-2-
GL4 and 0, 100 or 400 ng pMT23-HA-GSK3(S9A) for 48 h. Luciferase was normalised for transfection efficiency (-galactosidase activity) and mean
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tically significant 60% increase in luciferase activity was ob-
served following 99021 treatment, indicating a 60% loss of
Drosha activity upon GSK3 inhibition (Figure 1Fii). No
alteration to luciferase activity was observed upon trans-
fection of a Drosha reporter lacking a pri-miR sequence
(Figure 1Fi). In addition, a significant dose-dependent in-
crease in luciferase activity (reduction of Drosha activity)
was observed following co-transfection of the Drosha re-
porter plasmid with increasing amounts of GSK3-K85R
(Figure 1Fiii). These data suggest that GSK3 regulates
miR levels by modulating Drosha activity towards pri-miR
substrates.
Taken together, these data represent the first evidence of a
role forGSK3 inmiRmaturation in human cells. Our find-
ings indicate that GSK3 inhibition reduces miR biogen-
esis by repressing Drosha activity towards pri-miRs, lead-
ing to accumulation of miR precursors. Thus, GSK3 may
be a miR maturation-enhancing factor. This is in agree-
ment with the demonstration by Wu et al. that 90.4% of
differentially-regulatedmiRswere downregulated following
99021 treatment of mouse embryonic stem cells (33).
Constitutively active GSK3 S9A mutant increases Drosha
cleavage activity and enhances MiR biogenesis
To provide further evidence for the importance of GSK3
activity for miR maturation, converse experiments were
performed using a vector expressing constitutively active
GSK3: GSK3-S9A. Transfection of GSK3-S9A into
HEK293T significantly increased levels of mature miR-27a,
miR-23a, miR-24, miR-141 and miR-182 by up to 7.5-fold
(Figure 2A), with similar effects also observed in HeLa cells
(Supplementary Figure S2A). In contrast, levels of corre-
sponding pri-miR precursors were significantly reduced by
up to 80% in HEK293T cells following GSK3-S9A trans-
fection (Figure 2B). As anticipated, GSK3-S9A did not
alter protein levels of MP and RISC components, including
Drosha (Figure 2C), and showed comparable localisation
to bothWT and dominant-negative GSK3 upon transfec-
tion into Cos-1 and LNCaP cells (Supplementary Figure
S4). However, expression of constitutively activate GSK3
in Cos-1 cells significantly reduced luciferase activity of the
Drosha reporter vector by up to almost 40%, indicating
enhanced Drosha activity in the presence of GSK3-S9A
(Figure 2D). These data support the hypothesis that active
GSK3 promotes miR biogenesis by increasing Drosha-
mediated cleavage of pri-miRs. If this is the case, GSK3
activity should increase, and its inhibition decrease, pre-
miR levels. Thus, in vitro pri-miR processing assays were
performed, in which in vitro transcribed and radio-labelled
pri-miR-23a27a24-2 was incubated with Flag-Drosha MP
complex immunoprecipitated from HEK293T cells post-
transfection with WT, constitutively-active or dominant-
negative GSK3. As anticipated, no pre-miRwas produced
in the absence of Flag-Drosha (Figure 2E). Further, WT
GSK3 enhanced production of pre-miRs in the presence
of Drosha compared to Drosha alone (Figure 2E). S9A-
GSK3 did not appear to increase pre-miR levels versus
WTunder these experimental conditions, however, addition
of dominant-negative GSK3-K85R significantly reduced
pre-miR levels (Figure 2E). Pre-miRbandswere observed in
alignment with the 60 nt RNAmarker (Figure 2E and Sup-
plementary Figure S3), which is consistent with expected
pre-miR-23a, −27a and −24 sizes of 57 nt, 62 nt and 59 nt,
respectively. Additional experimental replicates are shown
(Supplementary Figure S2B) andWestern blotting was per-
formed on input cell lysates to demonstrate equal expres-
sion of the GSK3 and Flag-Drosha constructs (Supple-
mentary Figure S2C). Uncropped images of different expo-
sure lengths from one biological replicate are shown (Sup-
plementary Figure S3) to allow clear visualisation of both
pre-miR bands and RNA size markers.
To confirmGSK3-enhanced pre-miR production, small
RNAs (<200 nt) were isolated fromHEK293T cells treated
with 99021 or transfected with S9A-GSK3 or K85R-
GSK3 and qPCR performed using primers targeting the
miR-27a stem-loop, without amplification of pri-miRs due
to size selection. It was demonstrated that 99021 treat-
ment significantly reduced levels of pre-miR-27a (Fig-
ure 2Fi), whilst constitutively-active S9A-GSK3 increased
pre-miR-27a levels. Dominant-negative K85R-GSK3 de-
creased pre-miR levels (Figure 2Fi), in agreement with Fig-
ure 2E and effects observed upon 99021 treatment. As ex-
pected, GSK3-WT and -S9A decreased levels of pri-miR-
23a27a24-2, whilst 99021 and K85R-GSK3 increased pri-
miR-23a27a24-2 levels under the same experimental condi-
tions (Figure 2Fii).
GSK3 modulation alters Drosha association with pri-miRs
To further elucidate the mechanism(s) by which GSK3
modulates Drosha activity, RNA immunoprecipitation as-
says were performed to evaluate the effects of GSK3 on
association of Drosha with pri-miR species. HEK293T cells
were transfected with a Flag-tagged Drosha expression vec-
tor and either dominant-negative or constitutively-active
GSK3 mutant expression vector, followed by immuno-
precipitation of the MP complex using anti-Flag antibody,
RNA extraction and qRT-PCR for pri-miRs. It was demon-
strated that transfection of Flag-Drosha significantly in-
creased pri-miR-23a27a24-2 and pri-miR-182 pull-down
by up to 4-fold over background binding (Figure 3Ai and
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
± SEM of three independent experiments performed in duplicate is shown. (E) In vitro Drosha-mediated pri-miR processing assay analysis of pre-miR
levels following incubation of in vitro transcribed radio-labelled pri-miR-23a27a24-2 with Microprocessor complex immunoprecipitated from HEK293T
cells transfected with Flag-Drosha±GSK3-WT, -S9A or -K85R for 48 h. Products of in vitro processing reactions were resolved on a 6% acrylamide:urea
gel and exposed to film. A representative image of (i) three independent experiments is shown. Densitometry was performed using Image J software (ii
and iii). Columns: mean ± SEM for three independent experiments. Images of biological replicate experiments and complete gel images can be found in
Supplementary Figure S2B and S3. (F) qRT-PCR analysis of (i) pre-miR-27a and (ii) pri-miR-23a27a24-2 levels in HEK293T cells treated with either 2
M 99021, an equal volume of DMSO or transfected with pMT23-HA-GSK3(WT) pMT23-HA-GSK3(S9A) or pMT23-HA-GSK3(K85R) for 48 h.
L19 was used as a normalisation gene. Columns: mean ± SEM for three independent experiments performed in duplicate. *P ≤ 0.05, **P ≤ 0.005, ***P
≤ 0.0001. See also Supplementary Figures S2 and S3.
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Figure 3. GSK3 regulates pri-MiR association with Drosha. (A and B) RNA-immunoprecipitation analysis of association of pri-miRs with Drosha in
HEK293T cells ± (A) dominant-negative GSK3-K85R or (B) constitutively-active GSK3-S9A. Cells were transfected with Flag-Drosha ± (A) GSK3-
K85R or (B) GSK3-S9A, then immunoprecipitated with anti-Flag antibody-bound beads and subjected to qRT-PCR analysis using (i) pri-miR-23a27a24-
2, (ii) pri-miR-141/200c and (iii) pri-miR-182 primers. Columns: mean ± SEM for three independent experiments performed in duplicate, *P ≤ 0.05
compared to mock-transfected cells. (C) RNA-immunoprecipitation analysis of association of pri-miRs with wild-type GSK3 in HEK293T cells. Cells
were transfectedwithHA-GSK3, immunoprecipitatedwith anti-HA antibody-bound beads and subjected to qRT-PCRanalysis using pri-miR-23a27a24-
2, pri-miR-141/200c and pri-miR-182 primers. Columns: mean ± SEM for three independent experiments performed in duplicate, *P ≤ 0.05 compared
to empty vector-transfected cells. (D) RNA-immunoprecipitation analysis of association of pri-miR-23a27a24-2 with constitutively-active and dominant-
negative GSK3 mutants in HEK293T cells. Cells were transfected with HA-GSK3-WT, HA-GSK3-S9A or HA-GSK3-K85R, immunoprecipitated
with anti-HA antibody-bound beads and subjected to qRT-PCR analysis using pri-miR-23a27a24-2 primers.Columns:mean± SEM for three independent
experiments performed in duplicate, *P ≤ 0.05. See also Supplementary Figure S5.
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iii), with a similar trend observed for pri-miR-141/200c
(Figure 3Aii). Interestingly, addition of GSK3-K85R to
this system significantly reduced Drosha:pri-miR associa-
tion to background levels (Figure 3A). These data indi-
cate that dominant-negative GSK3 reduces global asso-
ciation of pri-miRs with Drosha, thereby inhibiting miR
maturation. Conversely, addition of constitutively active
GSK3-S9A significantly enhanced association of pri-miR-
141/200c with Drosha by 5-fold (Figure 3Bii) and the same
trend was observed for both pri-miR-23a27a24-2 and pri-
miR-182 (Figure 3Bi and iii).
To investigate whether GSK3 itself can directly bind
to pri-miRs, and its involvement in MP-mediated pri-
miR cleavage, HEK293T cells were transfected with HA-
tagged wild-type, dominant-negative or constitutively-
active GSK3 mutant expression vectors, followed by
RNA immunoprecipitation using anti-HA antibody. It was
found that pull-down of pri-miR-23a27a24-2 and pri-miR-
141/200c was significantly increased in the presence of HA-
GSK compared to empty vector control (Figure 3C), sug-
gesting either that GSK3 is able to directly interact with
pri-miRs, or that the presence of GSK3 in the MP (or
MP-like complex) increases association of pri-miRs with
this complex. Given the small fraction of pri-miR recov-
ered in this assay, the latter may be the likelier explana-
tion. It was also observed that constitutive activation of
GSK3 increased its association with pri-miR-23a27a24-2,
whilst dominant-negative GSK3 showed significantly re-
duced binding to pri-miR-23a27a24-4 compared to wild-
type (Figure 3D). Similar effects were observed for pull
down of pri-miR-141/200c and pri-miR-182 (Supplemen-
tary Figure S5). These data support our hypothesis that
GSK3 enhances miR biogenesis by increasing association
ofDrosha with pri-miR species in a global manner, and that
the presence of GSK3 within the MP complex increases
pri-miR binding to the complex, possibly through direct as-
sociation of GSK3 with pri-miRs.
GSK3 alters Drosha association with MP components and
interacts with DGCR8 and p72 in a RNA-dependent manner
to modulate Pri-MiR to Pre-MiR processing
To investigate if a direct interaction between GSK3 and
MP components may facilitate the GSK3-mediated in-
crease in Drosha activity, immunofluorescent antibody
staining was performed on PC3 prostate cancer cells to as-
sess colocalisation of endogenous proteins. GSK3 stain-
ing (green) was observed in the cytoplasm, but discrete flu-
orescence was also observed in the nucleus, where it showed
colocalisation with both Drosha and its cofactor, DGCR8
(Figure 4A – colocalisation indicated by yellow staining).
This supports the possibility of interaction betweenGSK3
andMP proteins. GSK3 was also found to colocalise with
Drosha in the nuclei of Cos-1 and LNCaP cells following
transient transfection of pMT23-HA-GSK3 and pCK-
Flag-Drosha (Supplementary Figure S4). GSK3-S9A and
GSK3-K85R demonstrated identical subcellular localisa-
tion to GSK3-WT in both Cos-1 and LNCaP cells follow-
ing transient transfection (Supplementary Figure S4).
In order to further address the possibility of interac-
tion between Drosha and GSK3, and to evaluate the ef-
fects of GSK3 activity on association of Drosha with
other components of the MP complex, HEK293T cells
were treated with 99021 for 48h and immunoprecipita-
tion performed using Drosha antibody-bound beads. An
interaction between Drosha and GSK3 was not evident
(data not shown), although it is possible that such interac-
tions are so transient as to be undetectable using this ap-
proach. However, a significant 50% reduction of Drosha
association with MP components, DGCR8 and p72, was
observed following 99021 treatment (Figure 4B, Supple-
mentary Figure S6A)), indicating that GSK3 may facil-
itate or enhance interactions between Drosha and its MP
cofactors. To corroborate these findings, HEK293T cells
were co-transfected with Flag-Drosha and constitutively-
active/dominant-negative GSK3 mutants and immuno-
precipitation experiments performed using anti-Flag anti-
body. Again, no evidence was found for a physical interac-
tion betweenDrosha and eitherGSK3mutant under these
conditions (Figure 4C,Supplementary Figure S6B middle
panel - bands in IP lanes are non-specific and are observed
following addition of secondary antibody only). However,
it was demonstrated that constitutively active GSK3-S9A
significantly increased (by 50%) the association of Drosha
with DGCR8, a MP cofactor that is responsible for cor-
rect orientation of Drosha on the pri-miR hairpin and is
required for efficient Drosha RNase activity (Figure 4C
i,ii and Supplementary Figure S6B). Addition of GSK3-
K85R reduced Drosha:DGCR8 binding compared to non-
GSK3 mutant-transfected cells by 30%. Together these
data suggest that GSK3 enhances interactions between
Drosha and its vital MP cofactors DGCR8 and p72 to ac-
celerate pri-miR processing and promote miR biogenesis.
Since no evidence of direct GSK3:Drosha interaction was
seen, it was hypothesised that GSK3 may directly inter-
act with DGCR8 and/or p72. To test this, HEK293T cells
were treated with 99021 for 48 h and immunoprecipita-
tion performed using GSK3 antibody-bound beads. In-
teraction of endogenous GSK3 with both DGCR8 and
p72 was confirmed, and reduced by ∼40% upon treatment
with GSK3 inhibitor (Figure 4D). In confirmation of this
finding, DGCR8 and p72 were also demonstrated to inter-
act with HA-tagged exogenous GSK3 (Figure 4E). Addi-
tion of dominant-negative GSK3-K85R reduced these as-
sociations by 60% compared to GSK3-WT (Figure 4E).
However, whilst GSK3-S9A non-significantly increased
Drosha association with DGCR8 (Figure 4Eii), the pres-
ence of GSK3-S9A significantly reduced interaction of
Drosha with p72 (Figure 4Eiii). These data confirm binding
of GSK3 to MP components, DGCR8 and p72, modulat-
ing Drosha activity and miR accumulation.
Immunoprecipitation cannot demonstrate whether inter-
action between GSK3 and DGCR8 and p72 is direct or
occurs via another factor, such as a pri-miR. To investigate
the ability ofWTGSK3 to interact with the above proteins
in the absence of pri-miRs, GSK3 IP experiments were
performed with or without RNase A treatment. Associa-
tion ofGSK3with both p72 andDGCR8was significantly
reduced by over 50% following RNase A treatment (Figure
4F, Supplementary Figure S6C). This suggests that anRNA
species (mostly likely pri-miRs, given the known localisa-
tion of p72, DGCR8 and GSK3 in the MP) is required
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Figure 4. GSK3 modulates association of Drosha with DGCR8 and p72 and binds to microprocessor components to facilitate Drosha-mediated pri-
miR production. (A) Analysis of GSK3 colocalisation with DGCR8 and Drosha in HEK293T cells by immunofluorescent antibody staining. Green,
GSK3; red, DGCR8 or Drosha; yellow, colocalisation (as indicated by arrows). Scale: as indicated by bars. Images are representative of two independent
experiments, with five fields imaged per experiment. (B) Immunoprecipitation (IP) analysis of effects of 48 h 99021 (2 M) treatment on interaction of
endogenous Drosha with p72 andDGCR8 in HEK293T cells. 99021-treated HEK293T lysates were incubated with Drosha antibody- or rabbit IgG-bound
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to achieve the highest extent of association of GSK3 with
MP components.Minimal binding is retained in the absence
of RNA, although not significantly above background lev-
els (Figure 4F, Supplementary Figure S6C).
Taken together, these data demonstrate that GSK3 in-
teracts with the MP cofactors DGCR8 and p72 in a pri-
miR-enhancedmanner to increase Drosha activity and pro-
mote miR biogenesis.
GSK3 nuclear localisation is required for its miR
biogenesis-enhancing effects
In order to demonstrate the requirement of nuclear locali-
sation of GSK3 for its biogenesis-promoting effects, nu-
clear localisation signal (NLS)-mutant HA-GSK3 con-
structs were generated. A putative NLS has been described
between amino acids 85 and 123 of GSK3 (45). HEK293T
cells were transfected with HA-GSK3-K85A,K86A, HA-
GSK3-R96A and HA-GSK3-R102G,K103A (as these
have been previously shown nuclear exclusion (45)) and sub-
cellular fractionation performed. WT GSK3 was found
in both cytoplasmic and nuclear compartments (Figure
5A). HA-GSK3-R96A and HA-GSK3-R102G,K103A did
not demonstrate altered localisation compared to WT
GSK3 (Figure 5A). HA-GSK3-S9A and HA-GSK3-
K85R also demonstrated similar localisation profiles to WT
(Supplementary Figure S7A). In contrast, HA-GSK3-
K85A,K86A was largely excluded from soluble nuclear
and chromatin-bound fractions of HEK293T cells. Nu-
clear exclusion of HA-GSK3-K85A,K86A was confirmed
upon immunofluorescent antibody staining of HA and
Flag in LNCaP cells transfected with Flag-Drosha and
HA-GSK3-WT/ K85A,K86A (Figure 5B). To investigate
the impact of GSK3 nuclear exclusion on its interac-
tions with MP components, HEK293T cells were trans-
fected with HA-GSK3-WT or HA-GSK3-K85A,K86A
and IP performed using HA antibody-conjugated beads. It
was demonstrated that interaction of NLS-mutant GSK3
with DGCR8 is significantly reduced to background lev-
els compared to HA-GSK3WT interaction (Figure 5Ci,ii
and Supplementary Figure S7B). However, interaction of
GSK3 with p72 is only minimally reduced by muta-
tion of the NLS (Figure 5Ci,iii and Supplementary Fig-
ure S7B). This may be because, unlike DGCR8, p72 lo-
calises to the cytoplasm of HEK293T cells in addition
to the nucleus (Figure 5D). To investigate the functional
consequences of GSK3 nuclear exclusion on miR bio-
genesis, qPCR was performed for pri-miRs and mature
miRs following transfection of HEK293T cells with HA-
GSK3 WT or HA-GSK3-K85A,K86A. As anticipated,
HA-GSK3 WT significantly reduced levels of pri-miR-
23a27a24-2, −141/200c and −182 (Figure 5E). This ef-
fect was abolished by addition of HA-GSK3-K85A,K86A
(Figure 5E). In corroboration of this, GSK3-mediated in-
crease in mature miR levels was reduced to baseline lev-
els in the presence of GSK3 NLS mutant (Figure 5F).
Taken together, these data confirm that nuclear localisation
of GSK3 is required for its miR biogenesis-enhancing ef-
fects.
GSK3 phosphorylates Drosha at S300 and S302 to modulate
Drosha associationwithDGCR8 and p72, alterDrosha cleav-
age activity and regulate mature MiR levels without altering
Drosha localisation
Having established that GSK3 activity promotes miR bio-
genesis as a MP component through increasing association
of Drosha with pri-miRs and cofactors, and in light of re-
ports that Drosha is a target for GSK3-mediated phos-
phorylation (34), we sought to investigate the impact of
such putative post-translational modifications on Drosha’s
pri-miR processing activity. This will allow us to discover
whether or not miR-modulatory effects of GSK3 are at-
tributable, at least in part, to its phosphorylation ofDrosha.
We sought first to confirm phosphorylation of Drosha
by GSK3 at S300 and S302. To this end, HEK293T cells
were treated with 99021 and lysates immunoprecipitated
using anti-phosphoserine antibody and subjected to im-
munoblotting for Drosha. Phosphorylation of Drosha was
confirmed, and found to be decreased following GSK3
inhibition by 99021 (Figure 6A), indicating that Drosha
is a substrate for GSK3 kinase activity. However, some
phospho-Drosha was still detectable following GSK3 in-
hibition (Figure 6A) implying that Drosha is also a sub-
strate for other kinases. To provide evidence for GSK3
phosphorylation of Drosha specifically at S300 and S302,
HEK293T cells were transfected with WT Flag-Drosha or
S300A302A phospho-mutant Flag-Drosha and treated with
99021, followed by anti-Flag immunoprecipitation and im-
munoblotting for phospho-serine. It was demonstrated that
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Protein G beads andWestern blotting performed for DGCR8 and p72. A representative image of three independent experiments is shown (i). Densitometry
was performed using Image J software, and IP protein levels displayed relative to input (i and iii). Images of biological replicate experiments can be found
in Supplementary Figure S5A. (C) IP analysis of interactions between exogenous Flag-Drosha and GSK3 or DGCR8. HEK293T cells were transfected
with Flag-Drosha ± GSK3-S9A/GSK3-K85R and subject to IP using anti-Flag antibody-bound beads, followed by Western blotting for GSK3, Flag
and DGCR8. A representative image of three independent experiments is shown (i). Densitometry was performed using Image J software, and IP protein
levels displayed relative to input (ii). Images of biological replicate experiments can be found in Supplementary Figure S5B. (D) IP analysis of effects of 48
h 99021 (2M) treatment on interaction of endogenous GSK3 with p72 and DGCR8 in HEK293T cells. 99021-treated HEK293T lysates were incubated
with GSK3 antibody- or mouse IgG-bound Protein G beads and Western blotting performed for DGCR8 and p72. A representative image of three
independent experiments is shown (i).Densitometry was performed using Image J software, and IP protein levels displayed relative to input (ii and iii). (E)
IP analysis of interactions between exogenous GSK3 and DGCR8 or p72. HEK293T cells were transfected with HA-GSK3-WT, HA-GSK3-S9A or
HA-GSK3-K85R and subject to IP using anti-HA antibody-bound beads, followed by Western blotting for p72, DGCR8 and HA. A representative blot
of three independent experiments is shown (i). Densitometry was performed using Image J software, and IP protein levels displayed relative to input (ii and
iii). (F) IP analysis of interactions between GSK3 and DGCR8 or p72 following RNase A treatment. HEK293T cells were transfected with HA-GSK3-
WT and subject to IP using anti-HA antibody-bound beads, followed by RNase A treatment (200g/ml). Western blotting for p72, DGCR8, Drosha and
HA was performed. A representative blot of three independent experiments is shown (i). Image J software was used for densitometry, and IP protein levels
displayed relative to input (ii and iii). Images of biological replicate experiments can be found in Supplementary Figure S5C. (A-F) Columns represent
mean ± SEM for three independent experiments. *P ≤ 0.05, **P ≤ 0.001. See also Supplementary Figure S6.
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Figure 5. GSK3 nuclear localisation is required for its MiR biogenesis enhancing effects. (A) Western blot analysis of HA-GSK3 protein levels in
cytoplasmic, soluble nuclear and chromatin fractions of HEK293T cells transfected with pMT23-HA-GSK3-WT, pMT23-HA-GSK3-K85A,K86A,
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phosphorylation of WT Flag-Drosha is reduced following
GSK3 inhibition (Figure 6Bi,ii), corroborating Drosha as
a GSK3 substrate. In addition, phosphorylation of Flag-
Drosha containingmutated S300 and S302 residues is reduced
compared to Flag-Drosha-WT and is not lost following
GSK3 inhibition (Figure 6Bii), supporting the hypothe-
sis that GSK3 can phosphorylate Drosha at S300 and S302.
Indeed, levels of phospho-Drosha are increased after 99021
treatment following ablation of S300 and S302 phosphoryla-
tion sites (Figure 6B). The differential effects of WT Flag-
Drosha or S300A302A phospho-mutant Flag-Drosha are not
attributable to altered Drosha localisation, since these con-
structs show comparable localisation profiles upon subcel-
lular fractionation of transfected HEK293T cells (Supple-
mentary Figure S8A).
To directly demonstrate phosphorylation of Drosha at
S300 and/or S302 by GSK3, in vitro kinase assays were
performed, whereby recombinant GSK3 was incubated
with 25aa peptides corresponding to WT or S300A,S302A-
mutant Drosha in the presence of ( -32P)-ATP. Observed
phosphorylation of WT Drosha peptide in the presence of
GSK3 was lost upon mutation of S300 and S302 residues
(Figure 6C, Supplementary Figure S8B), confirming that
GSK3 phosphorylates Drosha at either one or both of
these amino acids. We next sought to demonstrate the
functional consequences of GSK3 phosphorylation on
Drosha function. Cos-1 cells were transfected with the pre-
viously described Drosha reporter plasmid and either WT,
or phospho-mimic S300E,S302D Drosha expression vector,
which has been previously used to mimic phosphorylation
of Drosha at S300 and S302 (41). It was demonstrated that
Drosha S300E,S302D significantly reduced luciferase activ-
ity compared to WT Drosha, indicating increased pri-miR
cleavage by phospho-mimic Drosha (Figure 6D), and sug-
gesting that GSK3 phosphorylation of Drosha increases
its RNase activity. Equal expression of both Drosha con-
structs was confirmed by Western blotting (Figure 6D, in-
set). To investigate the influence of Drosha phosphoryla-
tion at S300 and/or S302 on Drosha association with its
MP cofactors, HEK293T cells were transfected with Flag-
Drosha WT or S300E,S302D phospho-mimic and IP per-
formed with Flag antibody-bound beads. Phospho-mimic
Drosha demonstrated significantly increased association
with both DGCR8 and p72 compared to WT Drosha (Fig-
ure 6E, Supplementary Figure S8C). To assess the func-
tional effects of phospho-Drosha on mature and pri-miRs,
HEK293T cells were transfected with Flag-Drosha WT
or S300E,S302D phospho-mimic and qPCR performed for
pri-miR-23a27a24-2 and −141/200c, and miR-23a, −27a,
−141 and−182. No significant difference in pri-miRs levels
was observed between Flag-Drosha WT and S300E,S302D-
transfected cells (Figure 6F), and whilst levels of miR-27a
and −182 were not significantly altered in the presence
of phospho-mimic Drosha (Figure 6Gii,iv), miR-23a and
miR-141 levels were significantly increased in the presence
of the S300E,S302D construct (Figure 6Gi,iii).
Together, these data suggest that GSK3 phosphorylates
Drosha at S300 and/or S302, leading to enhanced association
with p72 andDGCR8, increasedDroshaRNase activity to-
wards pri-miRs and increased levels of mature miRs.
GSK3-regulated MiR target proteins are increased follow-
ing GSK3 inhibition
Having established that GSK3ß regulates miR biogenesis,
we wished to determine whether this is likely to have down-
stream functional consequences. To this end, we studied the
effects of GSK3 inhibition on expression of the miR tar-
gets, at the levels of target 3′UTR activity, mRNA levels
and protein levels. Using a 3′UTR reporter construct for the
miR-27a targetACLY (in which theACLY 3′UTRwas sub-
cloned 3′ of the luciferase gene in the pMiRTarget vector), it
was found that luciferase activity was significantly increased
following addition of 99021 (Figure 7A). This suggests that
GSK3 inhibition relieves targeting of ACLY 3′UTR by
miR-27a, presumably by preventing GSK3-mediated up-
regulation of miR-27a. However, when the miR-27a bind-
ing site was mutated in this reporter construct, which abro-
gated the miR-27a-mediated loss of ACLY 3′UTR activity
observed for the WT construct (Supplementary Figure S9),
we observed significantly higher 3′UTR activity compared
to WT 3′UTR reporter (Figure 7A) – indicative of reduced
miR-27a binding to ACLY 3′UTR, which was additionally
not increased upon 99021 treatment. This supports the hy-
pothesis that 99021 treatment reduces miR-27a levels, re-
lieving repression of ACLY 3′UTR, and confirms that ef-
fects are specifically attributable to alterations in miR-27a,
since no increase in 3′UTR activity upon GSK3 inhibi-
tion was observed when the miR-27a binding site was mu-
tated. We next examined whether 99021 treatment affected
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
pMT23-HA-GSK3-R96A or pMT23-HA-GSK3-R102G,K103A for 48 h. HSP70 and PARP were used as a cytoplasmic and nuclear controls, respec-
tively. A representative blot of two independent experiments is shown. (B) Analysis of GSK3-WT and GSK3-K85A,K86A colocalisation with Drosha
in LNCaP cells by immunofluorescent antibody staining. LNCaP cells were transfected with pCK-Flag-Drosha ± pMT23-HA-GSK3-WT or pMT23-
HA-GSK3-K85A,K86A for 48 h, fixed and stained using antibodies against HA and Drosha. Green, HA-GSK3; red, Drosha; yellow, colocalisation.
Scale: as indicated by bars. Images are representative of two independent experiments, with four fields imaged per experiment. (C) IP analysis of inter-
actions between exogenous GSK3-WT/NLS mutant and DGCR8 or p72. HEK293T cells were transfected with pMT23, pMT23-HA-GSK3-WT or
pMT23-HA-GSK3-K85A,K86A and subject to IP using anti-HA antibody-bound beads. Western blotting for p72, DGCR8 and HA was performed. A
representative blot of three independent experiments is shown (i). Image J software was used for densitometry, and IP protein levels displayed relative to
input (ii,iii). Images of biological replicate experiments can be found in Supplementary Figure S7B. Columns represent mean± SEM for three independent
experiments. *P≤ 0.05. (D)Western blot analysis of p72 andDGCR8 protein levels in cytoplasmic and nuclear fractions ofHEK293T cells transfected with
pMT23-HA-GSK3-WT or pMT23-HA-GSK3-K85A,K86A for 48 h. HSP70 and PARP were used as a cytoplasmic and nuclear controls, respectively.
A representative blot of two independent experiments is shown. (E) qRT-PCR analysis of (i) pri-miR-23a27a24-2 (ii) pri-miR-141/200c or (iii) pri-miR-
182 levels in HEK293T cells transfected with pMT23-HA-GSK3-WT or pMT23-HA-GSK3-K85A,K86A for 48 h. L19 was used as a normalisation
gene. (F) qRT-PCR analysis of (i) miR-23a, (ii) miR-27a, (iii) miR-24, (iv) miR-141 and (v) miR-182 levels in HEK293T cells transfected with pMT23,
pMT23-HA-GSK3-WT or pMT23-HA-GSK3-K85A,K86A for 48 h. U18 was used as a normalisation gene. (E and F)Columns:mean± SEM for three
independent experiments performed in duplicate. *P ≤ 0.05, **P ≤ 0.005, See also Supplementary Figure S7.
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Figure 6. GSK3 phosphorylatesDrosha at S300 and S302 tomodulateDrosha associationwithDGCR8, alterDrosha cleavage activity and regulatemature
MiR levels without altering Drosha localisation. (A) IP analysis of effects of 48 h 99021 (2 M) treatment on endogenous Drosha phosphorylation. 99021-
treated HEK293T lysates were incubated with anti-phosphoserine–agarose and Western blotting performed for Drosha. A representative image of three
independent experiments is shown (i). Densitometry was performed using Image J software (ii,iii). (B) IP analysis of effects of 48 h 99021 (2 M) treatment
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levels of the 3′UTR of ACLY, ZEB1, PTEN and FOXO1
(miR-27a, miR-141, miR-141 and miR-182/27a targets, re-
spectively). It was demonstrated that forZEB1 (Figure 7Bii)
and PTEN (Figure 7Biii) 3′UTR levels were increased as
anticipated. However,ACLY 3′UTR levels were unchanged
(Figure 7Bi) and FOXO1 3′UTR levels decreased (Figure
7Biv) following addition of 99021. This may be due to
the different mechanisms of repression of these targets by
miR-27a. In cases where a miR acts via promoting transla-
tional repression, reduction of miR levels (here as a conse-
quence of GSK3ß inhibition) would result in derepression
of translation leading to increased protein levels without
necessarily affecting mRNA levels. However, in cases where
the miR exerts its effects via promoting trancript degrada-
tion, we would expect GSK3 inhibition to result in in-
creased mRNA expression with a corresponding increase
in protein levels. In accordance with this, both ACLY and
FOXO1 protein levels were increased following addition of
99021 (Figure 7C and F), as were protein levels of ZEB1
and PTEN (Figure 7D and E). These data demonstrate
that GSK3ß modulation of miR biogenesis has physiologi-
cal consequences through altering protein levels of GSK3ß-
regulated miR targets.
DISCUSSION
MiRs are dysregulated in many diseases, notably cancer,
where they can act as tumour suppressors or oncogenes. Re-
cent data have given tantalising clues as to the complex sig-
nalling pathways and cascades that impinge upon miR syn-
thesis, and it is vital to fully understand regulatory processes
governing miR biogenesis, and their perturbation in disease
states, in order to exploit miRs as an ‘untapped’ repository
of disease biomarkers and therapeutic targets.
GSK3 is a serine/threonine protein kinase that plays a
key role in signal transduction during processes such as cell
cycle progression, proliferation and inflammation through
phosphorylation of target proteins and shows altered activ-
ity in a number of cancers. Interestingly, GSK3 has been
shown to phosphorylate Drosha at residues S300 and S302,
and it has been suggested that such modifications are re-
quired for Drosha nuclear localisation (34). In addition,
small-molecule inhibition of GSK3 reduced mature lev-
els of more than 90% of miRs in mESCs, purportedly due
to loss of Drosha nuclear localisation (33).
We hypothesised that GSK3 could link pro-survival sig-
nalling pathways and miR biogenesis in human somatic
cells, and sought to examine the effects of GSK3 on
Drosha’s essential ribonuclease activity and to identify the
mechanism by which GSK3 modulates miR biogenesis.
We first transfectedHEK293T cells with dominant-negative
GSK3-K85R. This decreased mature miR levels, increased
pri-miR levels and reduced Drosha activity without alter-
ing Drosha protein levels or cellular localisation (Figure
1). These data suggested that inhibition of GSK3 reduces
Drosha-mediated pri-miR cleavage, thereby decreasing lev-
els of a number of different miRs. To corroborate this we
used a specific small-molecule inhibitor of GSK3, CHIR-
99021 (99021), which demonstrates greater than 500-fold
selectivity over closely-related kinases (22), and were able
to fully replicate the results obtained with GSK3-K85R:
decreased mature miR levels and increased pri-miR lev-
els, as attributable to reduced Drosha activity (Figure 1
and Supplementary Figure S1). These data further support
the hypothesis that GSK3 inhibition reduces miR bio-
genesis. Our demonstration of similar extents of regulation
for diverse miRs of different genomic contexts and sub-
ject to different modes of transcriptional regulation, when
taken together with the finding that 90.4% of differentially-
regulated miRs were downregulated following 99021 treat-
ment of mESCs (33), are suggestive of widespread GSK3
modulation of miR biogenesis, although how widespread
remains to be verified.
To provide additional evidence for the importance
of GSK3 in global miR maturation, we employed
constitutively-active GSK3-S9A and observed the con-
verse effect: an increase in Drosha activity, leading to in-
creased mature miR levels and a loss of pri-miRs (Figure
2A–D). Taken together, these data highlight an important
role for GSK3 in facilitating miR biogenesis by increasing
Drosha activity towards pri-miRs. To confirm our hypothe-
sis that GSK3 regulates miR biogenesis at the level of MP
activity, in vitro pri-miR processing assays were performed,
whereby in vitro transcribed pri-miR-23a27a24-2 was in-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
on phosphorylation of WT- or S300A,S302A phospho-mutant Flag-Drosha. HEK293T cells were transfected with WT- or S300A,S302A phospho-mutant
Flag-Drosha, treated with 2 M 99021 for 48 h, and subject to IP using anti-Flag antibody-bound beads, followed by Western blotting for phospho-serine
and Flag. A representative image of three independent experiments is shown (i). Densitometry was performed using (ii) Image J software. (A and B)
Colums: mean ± SEM for three independent experiments. (C) In vitro kinase assay analysis of GSK3 phosphorylation of WT or S300A,S302A-mutant
Drosha. Recombinant GSK3 was incubated with 25aa peptides corresponding to WT or S300A,S302A-mutant Drosha for 60 min in the presence of
( -32P)-ATP. Reaction products were spotted onto nitrocellulose membrane, washed and exposed to film. A representative image of three independent
experiments is shown (i). Images of biological replicate experiments can be found in Supplementary Figure S8B. Densitometry was performed using Image
J software (ii). Columns:mean ± SEM for three independent experiments. (D) Luciferase activity in extracts of COS-1 cells transfected with 100 ng CMV-
PrimiR-23a27a24-2-GL4 vector and 0, 100 or 250 ng pCK-Flag-Drosha(WT) or pCK-Flag-Drosha(S300E,S302D) for 48 h. Luciferase was normalised for
transfection efficiency (-galactosidase activity) and mean ± SEM of three independent experiments performed in duplicate is shown. Western blotting
analysis of Flag-Drosha protein levels was performed in HEK293T cells transfected with pCK-Flag-Drosha(WT) or pCK-Flag-Drosha(S300E,S302D)
for 48 h to demonstrate equal transfection efficiency and expression of the two plasmids in luciferase reporter assays. (E) IP analysis of interactions
between exogenous pCK-Flag-Drosha-WT/-S300E,S302D and DGCR8 or p72. HEK293T cells were transfected with pCK-Flag-Drosha(WT) or pCK-
Flag-Drosha(S300E,S302D) for 48 h and subject to IP using anti-Flag antibody-bound beads. Western blotting for p72, DGCR8 and Flag was performed.
A representative blot of three independent experiments is shown (i). Images of biological replicate experiments can be found in Supplementary Figure S8C.
Image J software was used for densitometry, and IP protein levels displayed relative to input (ii,iii). (F) qRT-PCR analysis of (i) pri-miR-23a27a24-2 or
(ii) pri-miR-141/200c levels in HEK293T cells transfected with pCK-Flag-Drosha(WT) or pCK-Flag-Drosha(S300E,S302D) for 48 h. L19 was used as a
normalisation gene. (G) qRT-PCR analysis of (i) miR-23a, (ii) miR-27a, (iii) miR-24, (iv) miR-141 and (v) miR-182 levels in HEK293T cells transfected
with pCK-Flag-Drosha(WT) or pCK-Flag-Drosha(S300E,S302D) for 48 h. U18 was used as a normalisation gene. (F and G) Columns: mean ± SEM for
three independent experiments performed in duplicate. *P ≤ 0.05, see also Supplementary Figure S8.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/45/5/2809/2290915 by U
niversity of G
lasgow
 user on 22 January 2019
2824 Nucleic Acids Research, 2017, Vol. 45, No. 5
99021: _ +
ZEB1
HEK293T
β-Actin
A
P
GSK3β
1
Pre-miR
2 3
4
5
p7
2
DROSHA
S300 S302
P P
DGCR8
GSK3β
DROSHA
p7
2 DGCR8
p7
2
DROSHA
S300 S302
DGCR8
+ GSK3β
- GSK3β
C
0
0.2
0.4
0.6
0.8
1
1.2
- +
M
ea
n 
A
C
LY
/β
-A
ct
in
 
R
el
at
iv
e 
Pr
ot
ei
n 
Le
ve
l
99021
ACLY
*
_ +99021:
HEK293T
ACLY
β-Actin
0
1
2
3
4
- +
M
ea
n 
ZE
B
1/
β-
A
ct
in
 
R
el
at
iv
e 
Pr
ot
ei
n 
Le
ve
l
99021
ZEB1
*
_ +99021:
HEK293T
FOXO1
β-Actin
99021:
β-Actin
PTEN
_ +
HEK293T
0
0.5
1
1.5
2
- +
M
ea
n 
PT
EN
/β
-A
ct
in
 
R
el
at
iv
e 
Ex
pr
es
si
on
99021
PTEN
ns
0
0.5
1
1.5
- +M
ea
n 
FO
XO
1/
β-
A
ct
in
 
R
el
at
iv
e 
Ex
pr
es
si
on
99021
FOXO1
*
B
0
0.5
1
1.5
2
DMSO 99021
ZE
B
1 
3’
U
TR
/L
19
 
R
el
at
iv
e 
Ex
pr
es
si
on
ZEB1 3’UTR
*
0
0.5
1
1.5
DMSO 99021
AC
LY
 3
'U
TR
/L
19
 
R
el
at
iv
e 
Ex
pr
es
si
on
ACLY 3'UTR(i) (ii)
ii)
0
0.5
1
1.5
DMSO 99021
FO
XO
1 
3’
U
TR
/L
19
 
R
el
at
iv
e 
Ex
pr
es
si
on
FOXO1 3’UTR
*
0
0.5
1
1.5
2
DMSO 99021
PT
EN
 3
’U
TR
/L
19
 R
el
at
iv
e 
Ex
pr
es
si
on
PTEN 3’UTR
*
(iii) (iv)
(i) (i) (i) (i)
D E F
(ii) (ii) (ii) (ii)
G
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
- + - +
WT miR-27a BS mut
M
ea
n 
Lu
c/
B
ga
l
ACLY 3'UTR Activity
*
** **
99021:
DROSHA
S300 S302
P P
DGCR8
GSK3β
p7
2
Figure 7. GSK3-regulated MiR target proteins are increased following GSK3 inhibition – mechanisms for enhanced MiR biogenesis by GSK3. (A)
Luciferase activity in lysates of HEK293T cells transfected with pMiRTarget-ACLY-WT or pMiRTarget-ACLY-miR27a binding site (BS) mutant (for
details see Supplementary Figure S9) and treated with 99021 (2 M, 24 h). Luciferase was normalised for transfection efficiency (-galactosidase activity)
and mean ± SEM of three independent experiments performed in duplicate is shown. (B) qRT-PCR analysis of (i) ACLY, (ii) ZEB1, (iii) PTEN and
(iv) FOXO1 3′UTR levels in HEK293T cells treated ± 99021 (2 M) for 72 h. L19 was used as a normalisation gene. Columns: mean ± SEM for three
independent experiments performed in triplicate. (C, D, E and F) Western blot analysis of (C) ACLY, (D) ZEB1, (E) PTEN (F) and FOXO1 protein
levels in lysates of HEK293T cells treated ± 99021 (2 M) for 72 h. -Actin was used as a loading control and for normalisation. Representative blots
of three independent experiments are shown (i). Densitometry was performed using Image J software (ii). Columns: mean ± SEM for three independent
experiments. *P ≤ 0.05. (G) A mechanism for enhanced miR biogenesis by GSK3. GSK3 phosphorylates Drosha at S300 and S302. This does not alter
levels of miR biogenesis proteins or modulate Drosha localisation but increases Drosha association with DGCR8, p72 and pri-miRs and enhances Drosha
pri-miR cleavage activity, reducing pri-miR and increasing mature miR levels. GSK3 achieves these effects as a component of theMicroprocessor, binding
to p72 and DGCR8 in an RNA-dependent manner.
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cubated with Flag-Drosha-containing MP immunoprecip-
itated from cells transfected with GSK3 mutant. Should
effects of GSK3 be at the level of pri-miR processing, we
anticipated pre-miR levels to be increased by GSK3-WT
and –S9A, and reduced by GSK3-K85R. Indeed, GSK3
increased Drosha-mediated pre-miR production, an effect
entirely abrogated byGSK3-K85R (Figure 2E). In support
of this, size-selection qPCR showed increased pre-miR lev-
els following GSK3-S9A transfection, whilst 99021 treat-
ment significantly reduced pre-miR-27a abundance (Figure
2Fi). This was corroborated by reduced pri-miR levels in
the presence of GSK3-WT and –S9A, and significantly in-
creased pri-miR-27a following GSK3-K85R transfection
(Figure 2Fii), in addition to enhanced Drosha reporter ac-
tivity in the presence of GSK3-S9A (Figure 2D). Thus, we
have provided substantial evidence that GSK3 acts at the
level of the MP to increase Drosha RNase activity and en-
hance pri-miR to pre-miR processing.
To elucidate the mechanism(s) by which GSK3 in-
fluences Drosha activity, we first examined the effect of
GSK3 inhibition or activation on Drosha:pri-miR bind-
ing using RNA-IP assays. It was found that dominant-
negative GSK3 significantly reduced association of
Drosha with several pri-miRs, whilst constitutively active
GSK3 increased it (Figure 3A and B). These data in-
dicate that GSK3 facilitates miR biogenesis by promot-
ing interaction between Drosha and pri-miRs. We then in-
vestigated the ability of GSK3 itself to associate with
pri-miRs, and found that the presence of HA:GSK3 re-
sulted in significantly increased anti-HA immunoprecipita-
tion of pri-miRswith respect to controls (Figure 3C). In cor-
roboration of this, dominant-negative GSK3 was found
to significantly reduce pri-miR-23a27a24-2 immunoprecip-
itation with reference to the wild-type protein, whilst the
constitutively-active protein increased pri-miR-23a27a24-
2 pull-down compared to WT-GSK3 (Figure 3D). There
are two possible interpretations of these data: firstly, that
GSK3 interacts directly with pri-miRs to enhance their
processing, perhaps retaining pri-miRs in the correct ori-
entation for efficient Drosha cleavage, since GSK3 lacks
RNase function; secondly, that GSK3 forms an intrin-
sic and important stimulatory component of a pri-miR-
binding complex (probably theMP), without direct pri-miR
association. The latter scenario is most likely, since GSK3
has neither been demonstrated nor predicted to contain
a DNA or RNA binding motif, and alters biogenesis of
all miRs assayed, regardless of level of pri-miR structure
branching, number of stem-loops in pri-miR or pri-miR
length, factors which would be expected to determine ex-
tent of GSK3 regulation if it bound pri-miRs directly. In-
terestingly, GSK3 is known to phosphorylate proteins, for
example, c-Jun, close to their DNA binding domain, alter-
ing affinity for DNA (46). Thus, it is a tempting hypoth-
esis that GSK3 additionally phosphorylates DGCR8 or
p72 near their RNA binding domains to increase affinity
for pri-miR substrates. Further, functional assignment of
GSK3 interactors in HepG2 cells identified 24 interactors
as ‘nucleic acid binding proteins’ – the largest functional
group described (47). This hints at previously unexplored
but important functions of GSK3 in RNA processing
pathways. It also appears that GSK3 may be prerequisite
for Drosha:pri-miR interaction, since pri-miR pulldown by
Drosha in the presence of dominant-negative GSK3 is re-
duced to background levels (Figure 3A).
To provide evidence for interactions between GSK3
and MP components in the nucleus, we first performed im-
munofluorescent staining and found evidence for nuclear
colocalisation of GSK3 with both Drosha and its cofac-
tor, DGCR8 (Figure 4A). Although GSK3 is often con-
sidered a cytoplasmic protein, our findings are supported
by the observation that 48% of GSK3 interacting proteins
are localised in the nucleus of cells (47), suggestive of an im-
portant nuclear role for GSK3. In order to investigate po-
tential interaction between GSK3 and Drosha, IP exper-
iments were performed. No interaction was identified be-
tween GSK3 and Drosha under our experimental condi-
tions, although it remains possible that such an association
exists but is below the detection threshold for IP, particu-
larly given the transient nature of kinase:substrate interac-
tions and demonstration by ourselves (Figure 6A–C) and
others (34) that Drosha is phosphorylated by GSK3. In-
deed, Drosha was not identified as a GSK3-binding pro-
tein in a recent GSK3 interactome study (47). We did,
however, demonstrate that GSK3modulation alters inter-
actions between Drosha and its MP cofactors: IP of en-
dogenous Drosha demonstrated significant loss of associ-
ation with both DGCR8 and p72 upon 99021 treatment
of HEK293T cells (Figure 4B), and constitutively active
GSK3 was shown to increase association of Drosha with
DGCR8 (Figure 4C). Interestingly, DGCR8 has been iden-
tified as a phospho-protein, with phosphorylation at 23 sites
demonstrated to increase its stability, resulting in a pro-
growth miR profile (48). Although JNK and ERK pro-
teins were identified as candidate kinases, the authors exam-
ined only a fraction of the kinome and additional potential
DGCR8-phosphorylating proteins are not known. Given
GSK3’s primary function as a kinase, it is an attractive hy-
pothesis that GSK3 could phosphorylate DGCR8 to in-
crease its stability, promoting its increased interaction with
Drosha and thus enhanced pri-miR cleavage. Indeed IP as-
says both with endogenous and HA-tagged GSK3 con-
firmed a previously undescribed interaction with DGCR8,
which was significantly diminished in the presence of 99021
(Figure 4D) or the dominant-negative mutant (Figure 4E).
Interestingly, GSK3 also demonstrated a novel interaction
with p72 (DDX17) (Figure 4D and E), a DEAD-box MP
cofactor that acts as a specificity protein for processing dis-
tinct subsets of miRs, and is important for miR matura-
tion (49). This provides additional evidence for the impor-
tance of GSK3 in miR biogenesis, and is of further inter-
est since p72 has been demonstrated to alternatively splice
GSK3 mRNA, increasing cellular levels of the shorter,
more catalytically active GSK3 isoform-1 (50). This pro-
vides another level of complexity to regulation of miR mat-
uration, whereby p72 not only regulates Drosha cleavage di-
rectly, but may also alter the equilibrium between the two
GSK3 isoforms in order to regulate MP activity. Recipro-
cal regulation is also possible via GSK3 phosphorylation
of p72, and/or the extent of the p72:GSK3 interaction it-
self. GSK3 has been demonstrated to interact with other
miR-regulatory and RNA-binding proteins: for example,
DDX1 and DDX21, which are closely-related to p72, and
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the heterogeneous nuclear ribonucleoproteins hnRNPA2B1
and hnRNPK, whose family member, hnRNPA1, is a key
MP component (47). Additionally, FUS and p68, further
components of the MP complex, were identified as partici-
pants in a cluster with GSK3 (47), adding further weight
to the argument that GSK3 facilitates miR biogenesis as
a component of the MP complex, although modulation of
Dicer activity by GSK3 has not be ruled out. Providing
further evidence of the importance of GSK3 in pri-miR
processing, its association with both DGCR8 and p72 was
lost upon RNase treatment of HEK293T cells (Figure 4F),
suggesting requirement of anRNA species, likely a pri-miR,
for association of GSK3 with MP components and en-
hancement of Drosha activity.
Having demonstrated interaction of GSK3 with p72
and DGCR8 that is reduced in the absence of RNA, we
sought to illustrate the requirement of GSK3 nuclear lo-
calisation for its miR biogenesis promoting activity. To this
end, we tested a number of previously reported NLS mu-
tants that had demonstrated nuclear exclusion in HEK293
and HeLa cells (45). HA-GSK3-K85A,K86A, but not –
R96A nor R102G,K103A, was found to be excluded from the
nucleus of HEK293T cells, as demonstrated both by sub-
cellular fractionation and immunofluorescent microscopy
(Figure 5A and B). Subsequent analyses showed that in-
teraction of HA-GSK3-K85A,K86A with DGCR8 is re-
duced compared to WT-GSK3 (Figure 5Ci,ii). Interest-
ingly, however, interaction with p72 was not altered by NLS
mutation (Figure 5Ci,iii). This is likely to be because p72
localises to the cytoplasm in addition to the nucleus (Fig-
ure 5D), thus its interaction with NLS mutant GSK3may
be representative of cytoplasmic binding. Functionally, pri-
miR levels were increased (Figure 5E) and mature miR lev-
els reduced (Figure 5F) in the presence of HA-GSK3-
K85A,K86A compared to the WT protein, suggesting nu-
clear localisation of GSK3 is required for optimal Drosha
cleavage of pri-miR substrates.
Given that GSK3 has been demonstrated to phospho-
rylate Drosha at S300 and S302 (34), we sought to clarify the
impact of such post-translational modifications on Drosha
RNase activity and to establish whether this is the mecha-
nism by which GSK3 alters Drosha:DGCR8, Drosha:p72
and Drosha:pri-miR interactions. We first used IP meth-
ods to demonstrate that levels of phospho-Drosha are re-
duced upon 99021 treatment (Figure 6A), suggesting that
GSK3 can phosphorylate Drosha in vitro. These data
confirm previous reports describing Drosha phosphoryla-
tion by this kinase (34,41). To provide evidence that such
phosphorylation occurs at S300 and S302, exogenous WT-
or S300A,S302A-Flag-Drosha were immunoprecipitated and
levels of serine-phosphorylated Drosha examined. It was
demonstrated that, in corroboration of the above discussed
data, phosphorylation of WT Flag-Drosha is significantly
decreased upon GSK3 inhibition, and that phosphoryla-
tion of S300A,S302A-Flag-Drosha is considerably reduced
compared to WT Drosha (Figure 6B). Interestingly, phos-
phorylated WT-Drosha is still detectable upon GSK3 in-
hibition (Figure 6A and B), suggesting that Drosha is also
serine-phosphorylated by other kinases. Further, levels of
phospho-Drosha are increased following 99021 treatment
of cells transfection with S300A,S302A-Flag-Drosha, raising
the possibility that inhibition of GSK3 derepresses activ-
ity of other kinases that phosphorylate Drosha at other
sites. Of note, our demonstration that abrogating GSK3-
mediated phosphorylation of Drosha at S300 and S302 (Sup-
plementary Figure S8A) does not alter its cellular localisa-
tion contrasts with previous data illustrating loss of Drosha
nuclear localisation upon 99021 treatment of mESCs (33),
and loss of nuclear Drosha in GSK3−/− MEFs compared
to WT cells (34). This may be due to differences in mecha-
nisms of GSK3 regulation of miR biogenesis between the
mouse embryonic cell lines used in prior studies (33,34), and
human HEK293T cells employed for our experiments, or
effects of GSK3 manipulation independent of kinase ac-
tivity at S300/S302.
Definitive evidence that GSK3 phosphorylates Drosha
at S300 and/or S302 has been provided by in vitro kinase as-
says: GSK3 can phosphorylate WT, but not S300A,S302A
mutant Drosha peptide in vitro (Figure 6C). In terms of
the impact of GSK3 phosphorylation of S300/S302 on
Drosha activity, luciferase activity of a pri-miR-23a27a24-
2-specific Drosha reporter construct was reduced following
addition of S300E,S302D phospho-mimic Drosha compared
to WT-Drosha (Figure 6D), indicating enhanced Drosha
cleavage. Further, phospho-mimic Drosha showed signif-
icantly enhanced interaction with its cofactors, DGCR8
and p72, as compared to WT-Drosha (Figure 6E), sug-
gesting that GSK3-mediated phosphorylation of Drosha
at S300 and S302 increases miR biogenesis by increasing
Drosha:cofactor interactions to promote pri-miR cleavage.
This is further supported by significantly increased lev-
els of miR-23a and −141 in HEK293T cells transfected
with phospho-mimicDrosha compared toWT (Figure 6G).
Minimal effects observed on pri-miR and mature miR-27a
and −182 levels may be attributable to maximal Drosha
activity in HEK293T cells transfected with WT Flag-
Drosha, such that Drosha activity towards pri-miRs can-
not be significantly elevated upon addition of Flag-Drosha-
S300E,S302D. Together, these data support the hypothesis
that GSK3 is the kinase responsible for Drosha phos-
phorylation at S300 and S302, leading to enhanced Drosha
RNase activity and miR accumulation.
To demonstrate the physiological relevance of GSK3
regulation of miR biogenesis, we examined 3′UTR activity
and protein levels of targets of miRs demonstrated above to
be regulated by GSK3. We demonstrated that 3′UTR ac-
tivity of ACLY (a target of GSK3-upregulated miR-27a)
was increased upon 99021 treatment (Figure 7A), which re-
ducesmiR-27a levels (Supplementary Figure S1D). In addi-
tion, protein levels of ACLY (miR-27a target – Figure 7C),
ZEB1 (miR-141 target – Figure 7D), PTEN (miR-141 tar-
get – Figure 7E) and FOXO1 (miR-182 and −27a target,
Figure 7F) were significantly increased following addition
of 99021, indicating derepression by their targeting miRs
due to loss of GSK3-enhancedmiR biogenesis. These data
demonstrates that GSK3 modulation of miR biogenesis
has physiological consequences by altering protein levels of
GSK3-regulated miR targets.
It is clear that GSK3 constitutes an important link be-
tween multiple pro-survival signalling pathways and miR
biogenesis. Perturbation of GSK3 activity may disrupt
the highly-regulated process of miR maturation and may
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play a role in disease pathology, carcinogenesis or mainte-
nance of an oncogenic phenotype. In addition, alterations
to the phosphorylation status of GSK3 in response to var-
ious stimuli may act as a rheostat that regulates miR bio-
genesis and the ratio of pri- to mature miRs by modulat-
ing Drosha activity. Further work is required to confirm
whether GSK3 regulation of miR maturation is a global
effect, and to establish whether GSK3 phosphorylates or
interacts with otherMP components in addition toDrosha,
DGCR8 and p72. It is possible that additional auxiliary
factors are required to confer specificity of GSK3 regula-
tion of miR biogenesis, and that GSK3 may contribute to
a pre-MP holoenzyme, associating with DGCR8, p72 and
other factors to assemble pre-MP configuration commen-
surate with Drosha binding. It will be very informative to
further examine the GSK3-regulated miRnome in human
cells to see if the miR subset identified is enriched for par-
ticular cellular functions or processes, as this could have im-
portant implications for GSK3 as a drug target in cancer,
where it displays contrasting and ambiguous roles.
In conclusion, these data are the first to identify an un-
expected and entirely novel important role for GSK3 in
post-transcriptional regulation of miR biogenesis as a com-
ponent of the MP and RNase cofactor: GSK3 binds to
p72 and DGCR8 in the nuclear MP in an RNA-dependent
manner, leading it to phosphorylate Drosha at S300 and S302
(Figure 6A–C). This does not alter levels of miR biogene-
sis proteins or modulate Drosha localisation, but increases
Drosha association with DGCR8, p72 and pri-miRs, and
enhances Drosha RNase and pri-miR cleavage activity, re-
ducing pri-miR and increasingmaturemiR levels, likely due
to stabilisation ofMP configuration. This has profound im-
plications for GSK3 as a drug target in cancer and other
pathologies, and for understanding miR biogenesis as a
highly complex and stringently-controlled process on which
a multitude of vital signalling cascades converge.
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